Table 1.
Detailed information on cancer types involved in this study
| Cancer type (abbreviated) | Cancer type (full name) | Sample size in paired comparison | Sample size in survival analysis | Percentage of censored samples (%) |
|---|---|---|---|---|
| BRCA | Breast invasive carcinoma | 112 | 980 | 89.1 |
| COAD | Colon adenocarcinoma | 26 | N/A* | N/A* |
| COADREAD§ | Colorectal adenocarcinoma | 32 | N/A* | N/A* |
| HNSC | Head and neck squamous cell carcinoma | 43 | 477 | 60.6 |
| KICH | Kidney chromophobe | 25 | N/A* | N/A* |
| KIPAN§ | Pan-kidney cohort (KICH + KIRC + KIRP) | 129 | 759 | 74.8 |
| KIRC | Kidney renal clear cell carcinoma | 72 | 461 | 67.9 |
| KIRP | Kidney renal papillary cell carcinoma | 32 | 257 | 85.6 |
| LIHC | Liver hepatocellular carcinoma | 50 | 320 | 70.0 |
| LUAD | Lung adenocarcinoma | 58 | 449 | 65.0 |
| LUSC | Lung squamous cell carcinoma | 51 | 444 | 59.5 |
| PRAD | Prostate adenocarcinoma | 52 | 445 | 97.8 |
| THCA | Thyroid carcinoma | 59 | 442 | 97.3 |
§COADREAD and KIPAN were not among original TCGA panel of cancer types; they were complex cancer types derived by authors of R package TCGA2STAT
*Three cancer types did not return at least ten significant DCLs in their respective CILP analysis, so they were not screened for prognosis DCLs via survival analysis